Get started
Author

Sueh‐li Lim

Observed names: S. Lim, Sueh-Li Lim, Sueh-li Lim, Suehli Lim
ORCID: 0000-0001-6990-8832
Observed ORCID: 0000-0001-6990-8832
OpenAlex ID: A5034443409
Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010
2025 · Simon Harrison, Phoebe Joy Ho, et al. · Blood · 27
European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma
2025 · Sueh‐li Lim, Monika Engelhardt, et al. · American Journal of Hematology · 16
Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
2026 · P. Joy Ho, Andrew Spencer, et al. · Journal of Clinical Oncology · 13
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
2025 · Nicholas Bingham, Jaynish Shah, et al. · Blood Cancer Journal · 8
PDF
A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Sueh-Li Lim, Bradley Augustson, et al. · Blood · 6
PDF
Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21
2024 · S. Lim, J. Reynolds, et al. · British Journal of Haematology · 5
Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma
2024 · Jessie Zhao, Tiffany Khong, et al. · Haematologica · 4
PDF
Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)
2024 · Sueh-Li Lim, John Reynolds, et al. · Blood · 4
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.
2025 · Sueh-Li Lim, Sridurga Mithraprabhu, et al. · Blood · 2
PDF
Real‐world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry
2023 · Sueh‐li Lim, Cameron Wellard, et al. · Internal Medicine Journal · 2
PDF
Putting the best foot forward when treating newly diagnosed multiple myeloma
2023 · Sueh‐li Lim, Andrew Spencer · Internal Medicine Journal · 2
Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
2022 · Sueh-li Lim, John Reynolds, et al. · Blood · 2
No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
2025 · Sueh‐li Lim, Cameron Wellard, et al. · British Journal of Haematology · 1
Supporting the Shift: Inpatient Review of BCMA CAR-T Therapy in Multiple Myeloma Reveals Early Safety and Feasibility for a Nurse Lead Outpatient Model of Care
2025 · Ty Simpson, Sriyani Parsons, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Circulating tumor DNA NRAS and TP53 mutations to identify ultra-high-risk primary refractory myeloma patients.
2026 · Sridurga Mithraprabhu, Thalia Perez-Suarez, et al. · Journal of Clinical Oncology
Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)
2025 · Sueh-Li Lim, John Reynolds, et al. · Blood
Abstract CT214: An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone: The IBIS Study AMaRC 20-01
2025 · Sueh-li Lim, John Reynolds, et al. · Cancer Research
Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
2021 · Sueh-li Lim, John Reynolds, et al. · Blood
‘Give them an INCH...’: dabigatran prescription in Victoria
2012 · Sueh-li Lim, Shaun Fleming, et al. · Pathology
Works count: 19
Citation count: 92
H-index: 5
I10-index: 3
Year
Topic
Type